CureDiab has received funding approval from the EFRE.NRW program GESÜNDER.IN.NRW for the next three years. The supported project focuses on the AI-driven identification and experimental validation of innovative drug candidates for metabolically driven systemic fibrosis (liver, kidney, and heart), including their evaluation in advanced human 3D liver-on-chip and FibroPaths® biochip models. The project is carried out in collaboration with renowned research institutions and technology companies from NRW and beyond.